Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice

Christina K. Baumgartner(AbbVie (United States)), Robert R. Montgomery(Versiti Blood Center of Wisconsin), Hartmut Weiler(Medical College of Wisconsin), Qizhen Shi(Children's Hospital of Wisconsin), Jeremy G. Mattson(Versiti Blood Center of Wisconsin)
Journal of Thrombosis and Haemostasis
August 6, 2016
10.1111/jth.13436
Cited by 21

Related Papers

Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council
|Journal of Pain|2016|3.1k
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis
|Nature Medicine|2007|378
Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies
|Journal of Clinical Investigation|2006|188
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
|Nature|2023|170
Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon.
|Journal of Clinical Investigation|1988|164